Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexeo Therapeutics, Inc. (LXEO) SEC filings page on Stock Titan aggregates the company’s public regulatory documents from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret key disclosures. As a Nasdaq-listed, clinical stage genetic medicine company, Lexeo uses filings such as Forms 8-K, 10-Q, and 10-K to report material events, financial results, and risk factors related to its gene therapy programs and corporate activities.
In its 8-K filings, Lexeo has reported items such as quarterly financial results, equity financings through underwritten public offerings and concurrent private placements, material definitive agreements like underwriting and securities purchase agreements, and registration rights agreements related to pre-funded warrants. The company also uses 8-Ks to furnish press releases that provide interim clinical and regulatory updates for its lead programs, LX2006 in Friedreich ataxia (FA) cardiomyopathy and LX2020 in PKP2-associated arrhythmogenic cardiomyopathy.
Filings also describe Lexeo’s interactions with the FDA, including feedback on potential accelerated approval pathways, participation of LX2006 in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, and regulatory designations such as Breakthrough Therapy, RMAT, Orphan Drug, Rare Pediatric Disease, and Fast Track. Corporate governance matters, executive appointments, compensation arrangements, and stockholder meeting results are likewise documented in SEC reports.
On Stock Titan, investors can review these filings alongside AI-generated highlights that summarize complex sections, helping to identify information on clinical development plans, capital structure changes, and other material disclosures. Real-time updates from EDGAR, combined with structured access to forms such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports, support deeper analysis of Lexeo’s regulatory and financial reporting history.
Richard Nolan Townsend, Chief Executive Officer and Director of Lexeo Therapeutics, Inc. (LXEO), reported an acquisition of common stock on 09/12/2025 under the companys 2023 Employee Stock Purchase Plan. The Form 4 shows the purchase of 2,193 shares at a price of $2.644 per share. After this transaction, the reporting person beneficially owns 222,251 shares in total, a position that explicitly includes 131,092 Restricted Stock Units.
The filing is executed by an attorney-in-fact and states the ESPP transaction is exempt under Rule 16b-3(c) and 16b-3(d). No derivative transactions or other disposals are reported on this Form 4.
Richard N. Townsend, Chief Executive Officer and Director of Lexeo Therapeutics, Inc. (LXEO), amended a Form 4 to correct previously reported insider sales. The amendment states that on 08/18/2025 Townsend disposed of 1,115 shares of Common Stock at a price of $4.668 per share to cover tax obligations arising from the release of restricted stock units (RSUs). After the reported disposition, Townsend beneficially owned 220,058 shares, which include 131,092 RSUs. The amended filing clarifies an earlier filing that had incorrectly reported a disposition of 2,735 shares. The amendment is signed by an attorney-in-fact on behalf of the reporting person.
Louis Edward Tamayo, Chief Financial Officer of Lexeo Therapeutics, acquired equity awards in the issuer. The Form 4 reports receipt of 45,000 restricted stock units (RSUs), each convertible into one share, and a stock option to purchase 280,000 shares at an exercise price of $4.79 per share. The RSUs carry no cash price and vest over time: 25% vest on August 15, 2026, with the remainder vesting in periodic installments thereafter under the company’s standard schedule. The option has a 10-year contractual term expiring August 28, 2035, with 25% of the option shares vesting on August 15, 2026, and the rest vesting monthly in equal installments thereafter, all subject to continued service. After these reported transactions, the filing shows 45,000 shares beneficially owned from RSUs and 280,000 option shares outstanding.
Lexeo Therapeutics reported an initial Section 16 Form 3 for Louis Edward Tamayo, who is identified as Chief Financial Officer and an officer/director of the company. The form, with an event date of
Jose Manuel Otero, Chief Technical Officer of Lexeo Therapeutics (LXEO), reported a sale of 2,848 shares of common stock on 08/18/2025 at a price of $4.668 per share to cover tax obligations arising from the release of restricted stock units (RSUs). After the reported transaction, he beneficially owns 60,372 shares, which include 49,687 RSUs. The filing identifies the transaction as a sale to cover taxes on RSU vesting and was submitted under a single reporting person designation. The form is signed by an attorney-in-fact on behalf of the reporting person.
Jenny Robertson, Chief Legal Officer of Lexeo Therapeutics, Inc. (LXEO), reported on a Form 4 that she sold 542 shares of the company's common stock on 08/18/2025 at a reported price of $4.668 per share. The filing states this sale was made to cover tax obligations arising from the release of restricted stock units (RSUs). After the transaction, Robertson beneficially owned 62,556 shares in total, which the filing clarifies includes 51,092 RSUs. The Form 4 was signed by an attorney-in-fact, Youjin Choi, on 08/20/2025.
Eric Adler, Chief Medical Officer of Lexeo Therapeutics, Inc. (LXEO), reported a transaction dated 08/18/2025 on Form 4 showing a sale of 608 shares of Common Stock at $4.668 per share. The filing explains the sale was to cover tax obligations on the release of restricted stock units (RSUs). Following the reported transaction, Adler beneficially owns 67,073 shares, which the filing notes includes 60,546 RSUs. The form was executed by an attorney-in-fact on 08/20/2025. The filing discloses the insider relationship and provides the required Section 16 reporting information.
Lexeo Therapeutics insider transaction: Chief Executive Officer and director Richard Nolan Townsend reported a sale of 2,735 shares of Lexeo Therapeutics common stock on 08/18/2025 at a price of $4.668 per share. The filing states the sale was executed to cover tax obligations related to the release of restricted stock units (RSUs).
After the reported transaction, Townsend beneficially owns 220,058 shares, which the filing notes include 131,092 RSUs. The report was filed as a Form 4 disclosing an individual insider sale described as a tax-withholding disposition of equity awards.
Insider sale to cover taxes at Lexeo Therapeutics (LXEO) Reporting person Tai Sandi, Chief Development Officer, reported a sale of 382 shares of common stock on 08/18/2025 at $4.668 per share. The filing states the sale was a "sale to cover" related to the release of restricted stock units (RSUs). After the transaction, the reporting person beneficially owned 58,860 shares, which the filer notes include 49,138 RSUs. The Form 4 was signed by an attorney-in-fact on 08/20/2025. No derivative transactions or other securities changes are reported in this filing.
Lexeo Therapeutics (LXEO) filed a Form 144 reporting a proposed sale of 2,848 common shares held by an insider following restricted stock vesting. The shares have an aggregate market value of $13,295.03 and represent a small fraction of the company's outstanding common stock of 54,001,214 shares. The filing lists Fidelity Brokerage Services LLC as the broker and an approximate sale date of 08/18/2025. The acquisition source is shown as restricted stock vesting on 08/15/2025 with payment characterized as compensation. No other sales in the past three months were reported.
FAQ
What is the current stock price of Lexeo Therapeutics (LXEO)?
What is the market cap of Lexeo Therapeutics (LXEO)?
